University of Texas Southwestern (UTSW) inked a collaborative research deal with Recombinetics (RCI) to identify key factors that improve the efficiency of generating interspecies chimera between pigs and humans. The parties entered into this agreement to contribute knowledge to the longer-term goal of advancing regenerative medicine through the reliable production of therapeutic human cells, tissues, and organs using blastocyst complementation. The goal: a more reliable supply of live-saving transplantable organs on demand that is not reliant on human donors.
TrialSite News breaks down this informational update for the benefit of those interested in regenerative medicine trends. Regenerative medicine, a branch of translational research in tissue engineering and molecular biology, deals with the process of replacing, engineering, or regenerating human or animal cells, tissues, or organs in the effort to restore or establish normal function.
Why did UTSW partner with RCI?
UTSW seeks the expertise of RCI in producing inter-species chimeras—specifically using blastocyst complementation method, where the host species is mutated to ablate a crucial organ or lineage, and t...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).